Literature DB >> 11640919

Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546.

N Nagarajan1, C Quast, A R Boxall, M Shahid, C Rosenmund.   

Abstract

Glutamate release at central synapses is transduced into a characteristic fast postsynaptic response by AMPA receptor gating and agonist affinity. The effect of two classes of modulators of AMPA receptor desensitization, the benzothiadiazides (cyclothiazide and IDRA 21) and the benzoylpiperidines (CX516 and CX546), were studied on gating kinetics of recombinant, native AMPA receptors and on synaptic currents. CX546 reduced the degree of desensitization more potently than CX516 or IDRA 21, but not as efficiently as cyclothiazide. In presence of CX516/CX546, desensitization of GluR2(flip) receptors was inhibited more than of GluR1(flip), whereas they had no effect upon response shape or conductance. CX546 increased agonist affinity threefold on nondesensitizing AMPA receptors by slowing agonist unbinding. Analysis of modulatory action suggests that, in contrast to cyclothiazide or IDRA 21, the Ampakine CX546 binds specifically to the agonist bound nondesensitized receptor, most likely acting by destabilizing the desensitized receptor conformation. All modulators tested showed higher efficiency on native receptors as compared to homomeric receptors. At the glutamatergic synapse, evoked synaptic amplitudes were weakly potentiated, while EPSC decay was slowed by nearly a factor of three in the presence of CX546 or cyclothiazide. In the presence of CX546, the current induced by short pulses of glutamate from recombinant GluR2 receptors decayed with a time course that was approximately twentyfold faster than EPSCs. The unique properties of CX546 may be beneficial for therapeutical use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11640919     DOI: 10.1016/s0028-3908(01)00133-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Micro-electrode array recordings reveal reductions in both excitation and inhibition in cultured cortical neuron networks lacking Shank3.

Authors:  C Lu; Q Chen; T Zhou; D Bozic; Z Fu; J Q Pan; G Feng
Journal:  Mol Psychiatry       Date:  2015-11-24       Impact factor: 15.992

3.  Targeting AMPA receptor gating processes with allosteric modulators and mutations.

Authors:  Nicholas A Mitchell; Mark W Fleck
Journal:  Biophys J       Date:  2007-01-05       Impact factor: 4.033

Review 4.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.

Authors:  Steven M Paul; James J Doherty; Albert J Robichaud; Gabriel M Belfort; Brian Y Chow; Rebecca S Hammond; Devon C Crawford; Andrew J Linsenbardt; Hong-Jin Shu; Yukitoshi Izumi; Steven J Mennerick; Charles F Zorumski
Journal:  J Neurosci       Date:  2013-10-30       Impact factor: 6.167

6.  AMPAkines and morphine provide complementary analgesia.

Authors:  Yongjun Sun; Kevin Liu; Erik Martinez; Jahrane Dale; Dong Huang; Jing Wang
Journal:  Behav Brain Res       Date:  2017-07-19       Impact factor: 3.332

7.  AMPAkines have novel analgesic properties in rat models of persistent neuropathic and inflammatory pain.

Authors:  Alexander M Le; Michelle Lee; Chen Su; Anthony Zou; Jing Wang
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

Review 8.  Chronic intermittent hypoxia-induced deficits in synaptic plasticity and neurocognitive functions: a role for brain-derived neurotrophic factor.

Authors:  Hui Xie; Wing-ho Yung
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

9.  AMPAkines Target the Nucleus Accumbens to Relieve Postoperative Pain.

Authors:  Chen Su; Hau Yeuh Lin; Runtao Yang; Duo Xu; Michelle Lee; Natalie Pawlak; Monica Norcini; Alexandra Sideris; Esperanza Recio-Pinto; Dong Huang; Jing Wang
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

10.  Modulation of agonist binding to AMPA receptors by 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine (CX546): differential effects across brain regions and GluA1-4/transmembrane AMPA receptor regulatory protein combinations.

Authors:  Kyle E Montgomery; Markus Kessler; Amy C Arai
Journal:  J Pharmacol Exp Ther       Date:  2009-08-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.